Corbus Pharmaceuticals Holdings, Inc.(CRBP)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CRBP is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $36.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Corbus Pharmaceuticals Holdings, Inc. reports net income of $-35.0M, free cash flow of $-29.6M. Top institutional holders of CRBP by reported 13-F value include Cormorant Asset Management, ORBIMED ADVISORS, BlackRock, based on the most recent SEC filings. CRBP trades on the Nasdaq exchange and files with the SEC under CIK 1595097. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRBP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Corbus Pharmaceuticals Holdings, Inc. directly from SEC EDGAR.
Net Income
$-35.0M
Free Cash Flow
$-29.6M
CRBP key financials by period
Corbus Pharmaceuticals Holdings, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2021
10-K
$881.7K
$-45.6M
—
FY 2020
10-K
$3.9M
$-111.3M
—
FY 2019
10-K
$36.1M
$-71.5M
—
FY 2018
10-K
$4.8M
$-55.7M
—
FY 2017
10-K
$2.4M
$-32.4M
—
FY 2016
10-K
$1.9M
$-20.0M
—
Institutions holding CRBP
Institutional investors reporting a position in Corbus Pharmaceuticals Holdings, Inc. on SEC Form 13F.
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $36.1M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
Price Chart
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
